181 related articles for article (PubMed ID: 33199495)
21. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract][Full Text] [Related]
22. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
23. Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
Trigos AS; Pasam A; Banks P; Wallace R; Guo C; Keam S; Thorne H; ; Mitchell C; Lade S; Clouston D; Hakansson A; Liu Y; Blyth B; Murphy D; Lawrentschuk N; Bolton D; Moon D; Darcy P; Haupt Y; Williams SG; Castro E; Olmos D; Goode D; Neeson P; Sandhu S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764368
[TBL] [Abstract][Full Text] [Related]
24. CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
Marciscano AE; Barbieri CE
Eur Urol; 2020 Nov; 78(5):680-681. PubMed ID: 32381460
[No Abstract] [Full Text] [Related]
25. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
26. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.
Barata P; Ledet E; Manogue C; Cotogno P; Harris K; Lewis B; Layton J; Sartor O
Oncologist; 2020 Sep; 25(9):e1421-e1422. PubMed ID: 32592623
[No Abstract] [Full Text] [Related]
28. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
29. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Bayles I; Krajewska M; Pontius WD; Saiakhova A; Morrow JJ; Bartels C; Lu J; Faber ZJ; Fedorov Y; Hong ES; Karnuta JM; Rubin B; Adams DJ; George RE; Scacheri PC
J Clin Invest; 2019 Oct; 129(10):4377-4392. PubMed ID: 31498151
[TBL] [Abstract][Full Text] [Related]
31. CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
Chirackal Manavalan AP; Pilarova K; Kluge M; Bartholomeeusen K; Rajecky M; Oppelt J; Khirsariya P; Paruch K; Krejci L; Friedel CC; Blazek D
EMBO Rep; 2019 Sep; 20(9):e47592. PubMed ID: 31347271
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
[TBL] [Abstract][Full Text] [Related]
33. CDK12: cellular functions and therapeutic potential of versatile player in cancer.
Pilarova K; Herudek J; Blazek D
NAR Cancer; 2020 Mar; 2(1):zcaa003. PubMed ID: 34316683
[TBL] [Abstract][Full Text] [Related]
34. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
[TBL] [Abstract][Full Text] [Related]
35. Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer.
Sartor O; Jang A; Ledet E
Oncologist; 2023 Nov; 28(11):e1127-e1128. PubMed ID: 37589230
[TBL] [Abstract][Full Text] [Related]
36.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
37.
Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
[TBL] [Abstract][Full Text] [Related]
38. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
40. CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Wang X; Chen H; Luo J; Xie L
Eur Urol; 2020 Mar; 77(3):342-343. PubMed ID: 31694772
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]